XML 33 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Millions
3 Months Ended 33 Months Ended
Jul. 30, 2013
Mar. 31, 2016
Jun. 30, 2015
Mar. 31, 2016
U.S./RoW [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Expected upfront, non-contingent and time-based payments $ 374.0      
Upfront, non-contingent and time-based payments received       $ 312.0
Contingent payment 62.0      
Development and regulatory approval milestones 550.0      
Commercial sales milestone 325.0      
Shared development costs 233.0      
Additional consideration based on net sales description   Low 20% range    
U.S./RoW [Member] | FibroGen, Inc. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Shared development costs 116.5      
U.S./RoW [Member] | Development Milestones [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Receipt of development milestone payment     $ 15.0  
China [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contingent payment 20.0      
Development and regulatory approval milestones 161.0      
Commercial sales milestone 167.5      
Proceeds from upfront payments $ 28.2